Upgrade to SI Premium - Free Trial

Neurocrine Biosciences (NBIX)

155.64 -2.71 (1.71%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/3/26)

Latest Headlines

Neurocrine Bio. (NBIX) PT Raised to $253 at Citi September 3, 2026 5:02 AM - StreetInsider Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley August 13, 2026 8:09 AM - StreetInsider Neurocrine's Ingrezza study shows quality-of-life gains in TD patients August 12, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living August 12, 2026 8:30 AM - PR NewsWire Neurocrine starts Phase 1 trial of obesity drug NBIP-1968 August 7, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist August 7, 2026 8:30 AM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: Aug 04 Filed by: Onyia Jude August 5, 2026 5:36 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $213 at Truist Securities August 3, 2026 7:06 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX) August 3, 2026 6:54 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord August 3, 2026 6:41 AM - StreetInsider Form S-8 NEUROCRINE BIOSCIENCES July 31, 2026 4:11 PM - SEC Filing Form 8-K/A NEUROCRINE BIOSCIENCES For: May 14 July 31, 2026 4:05 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $249 at Citi July 31, 2026 1:28 PM - StreetInsider Wells Fargo on Neurocrine Bio. (NBIX): 'Defending NBIX, We Would Be Buyers Here' July 31, 2026 11:35 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $215 at Cantor Fitzgerald July 31, 2026 10:22 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $220 at TD Cowen July 31, 2026 9:09 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $190 at BMO Capital July 31, 2026 8:58 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $210 at Piper Sandler July 31, 2026 8:35 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $198 at RBC Capital July 31, 2026 8:22 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $215 at Stifel July 31, 2026 8:09 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $196 at Morgan Stanley July 31, 2026 8:01 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $204 at Needham July 31, 2026 7:24 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $225 at Baird July 31, 2026 7:20 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $222 at Guggenheim July 31, 2026 6:59 AM - StreetInsider Form 10-Q NEUROCRINE BIOSCIENCES For: Jun 30 July 31, 2026 6:06 AM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 28 Filed by: Norwalk Leslie V July 30, 2026 5:29 PM - SEC Filing Neurocrine Biosciences (NBIX) Tops Q2 EPS by 127c ; Offers Guidance July 30, 2026 4:19 PM - StreetInsider Form 8-K NEUROCRINE BIOSCIENCES For: Jul 30 July 30, 2026 4:02 PM - SEC Filing Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results July 30, 2026 4:01 PM - PR NewsWire Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: JPMORGAN CHASE & CO July 27, 2026 11:18 AM - SEC Filing Neurocrine Biosciences names three senior vice presidents July 23, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Announces Key Leadership Hiring, Promotions July 23, 2026 4:05 PM - PR NewsWire Neurocrine Bio. (NBIX) PT Raised to $193 at Morgan Stanley July 23, 2026 8:43 AM - StreetInsider Neurocrine Biosciences names Samir Siddhanti chief business officer July 21, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer July 21, 2026 4:05 PM - PR NewsWire Neurocrine Bio. (NBIX) PT Raised to $200 at Guggenheim July 21, 2026 6:45 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $200 at Wells Fargo July 17, 2026 6:42 AM - StreetInsider Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid July 15, 2026 11:53 AM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 10 Filed by: Delaet Ingrid July 13, 2026 4:28 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 09 Filed by: Lippoldt Darin July 13, 2026 4:27 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $170 at BMO Capital July 13, 2026 7:34 AM - StreetInsider Neurocrine Bio. (NBIX) PT Raised to $200 at Truist Securities July 13, 2026 7:08 AM - StreetInsider Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid July 10, 2026 4:39 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid July 9, 2026 6:41 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin July 9, 2026 4:27 PM - SEC Filing Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results July 9, 2026 4:01 PM - PR NewsWire Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid July 7, 2026 4:33 PM - SEC Filing Neurocrine Bio. (NBIX) PT Raised to $195 at RBC Capital July 7, 2026 7:55 AM - StreetInsider Neurocrine starts CAH drug trial in children under age 4 July 1, 2026 4:05 PM - StreetInsider Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia July 1, 2026 4:05 PM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: Jun 26 Filed by: Lippoldt Darin June 30, 2026 4:52 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin June 29, 2026 4:44 PM - SEC Filing Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin June 26, 2026 4:25 PM - SEC Filing Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX) June 22, 2026 9:29 AM - StreetInsider Neurocrine Biosciences (NBIX) Presents New VYKAT XR (diazoxide choline) Data June 15, 2026 4:11 PM - StreetInsider Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Foll June 15, 2026 4:10 PM - PR NewsWire Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY June 15, 2026 4:06 PM - StreetInsider Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 June 15, 2026 4:05 PM - PR NewsWire Neurocrine presents two-year CRENESSITY data showing growth improvements June 15, 2026 8:36 AM - StreetInsider Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 June 15, 2026 8:35 AM - PR NewsWire Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting June 15, 2026 8:30 AM - StreetInsider Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 June 15, 2026 8:30 AM - PR NewsWire Form 4 NEUROCRINE BIOSCIENCES For: Jun 05 Filed by: SHERWIN STEPHEN A June 9, 2026 5:41 PM - SEC Filing Form 4 NEUROCRINE BIOSCIENCES For: Jun 05 Filed by: Onyia Jude June 9, 2026 5:35 PM - SEC Filing Full Article List